These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28467330)

  • 41. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.
    Bianchi M; Festa V; Moretti A; Ciaco A; Mangone M; Tornatore V; Dezi A; Luchetti R; De Pascalis B; Papi C; Koch M
    Aliment Pharmacol Ther; 2011 Apr; 33(8):902-10. PubMed ID: 21366632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Board Review Vignette: Irritable Bowel Syndrome.
    Talley NJ
    Am J Gastroenterol; 2016 Sep; 111(9):1223-5. PubMed ID: 27527743
    [No Abstract]   [Full Text] [Related]  

  • 43. Quality of Life After Elective Laparoscopic Sigmoidectomy for Symptomatic Uncomplicated Diverticular Disease.
    Mari GM; Crippa J; Roscio F; Scandroglio I; Cocozza E; Borroni G; Berselli M; Achilli P; Costanzi ATM; Maggioni D;
    Surg Laparosc Endosc Percutan Tech; 2020 Sep; 31(2):193-195. PubMed ID: 32941354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease.
    Stallinger S; Eller N; Högenauer C
    Wien Klin Wochenschr; 2014 Jan; 126(1-2):9-14. PubMed ID: 24240607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
    Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
    N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Role of rifaximin in the treatment of colonic diverticular disease].
    Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M
    Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.
    Scaioli E; Colecchia A; Marasco G; Schiumerini R; Festi D
    Dig Dis Sci; 2016 Mar; 61(3):673-83. PubMed ID: 26458921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of rifaximin in gastrointestinal and liver diseases.
    Shayto RH; Abou Mrad R; Sharara AI
    World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Site and duration of abdominal pain discriminate symptomatic uncomplicated diverticular disease from previous diverticulitis patients.
    Carabotti M; Marasco G; Sbarigia C; Cuomo R; Barbara G; Pace F; Sarnelli G; Annibale B;
    Intern Emerg Med; 2024 Aug; 19(5):1235-1245. PubMed ID: 38671294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibiotic treatment of constipation-predominant irritable bowel syndrome.
    Pimentel M; Chang C; Chua KS; Mirocha J; DiBaise J; Rao S; Amichai M
    Dig Dis Sci; 2014 Jun; 59(6):1278-85. PubMed ID: 24788320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease.
    Colecchia A; Vestito A; Pasqui F; Mazzella G; Roda E; Pistoia F; Brandimarte G; Festi D
    World J Gastroenterol; 2007 Jan; 13(2):264-9. PubMed ID: 17226906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use and safety of rifaximin in children with inflammatory bowel disease.
    Muniyappa P; Gulati R; Mohr F; Hupertz V
    J Pediatr Gastroenterol Nutr; 2009 Oct; 49(4):400-4. PubMed ID: 19668011
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights.
    Strate LL; Modi R; Cohen E; Spiegel BM
    Am J Gastroenterol; 2012 Oct; 107(10):1486-93. PubMed ID: 22777341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.
    Papi C; Ciaco A; Koch M; Capurso L
    Aliment Pharmacol Ther; 1995 Feb; 9(1):33-9. PubMed ID: 7766741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
    Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review article: the current and evolving treatment of colonic diverticular disease.
    Tursi A; Papagrigoriadis S
    Aliment Pharmacol Ther; 2009 Sep; 30(6):532-46. PubMed ID: 19549266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
    Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of rifaximin-resistant Bifidobacterium longum W11 in subjects with symptomatic uncomplicated diverticular disease treated with rifaximin.
    Di Pierro F; Bertuccioli A; Pane M; Ivaldi L
    Minerva Gastroenterol Dietol; 2019 Dec; 65(4):259-264. PubMed ID: 31646852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A critical appraisal of advances in the diagnosis of diverticular disease.
    Tursi A
    Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):791-796. PubMed ID: 29888630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The influence of rifaximin on diverticulitis rate and quality of life in patients with diverticulosis.
    Banasiewicz T; Francuzik W; Bobkiewicz A; Krokowicz Ł; Borejsza-Wysocki M; Paszkowski J; Studniarek A; Krokowicz P; Grochowalski M; Szczepkowski M; Lorenc Z
    Pol Przegl Chir; 2017 Feb; 89(1):22-31. PubMed ID: 28522790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.